Weight Watchers is Novo Nordisk's latest partnersip.

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

WeightWatchers Clinic Members Can Access FDA-Approved Wegovy® for $299 in July, a $200 Savings Offer to Improve Access as WeightWatchers’ Trusted, Science-Backed Approach Continues to Lead the ...

Novo Nordisk's press release stated that the "FDA action date to decide on the Wegovy ® oral formulation NDA will be in Q4 2025." Thus, if approved, we can expect a launch in 2026.

As the only holistic platform focused on long-term weight health featuring the No. 1 doctor-recommended weight loss program included in the recently announced collaboration with Novo Nordisk, ...

Retail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially ...

Novo Nordisk is growing coverage of its Wegovy (semaglutide) injection 2.4 mg in the form of a new deal with WeightWatchers that takes effect July 1. 1 CenterWell Pharmacy will be the dispensing ...

The expanded collaboration comes amid Novo Nordisk’s broader strategy to dominate the obesity treatment space. The company recently said it is advancing both oral and injectable formulations of its ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

UnitedHealth Group’s ( UNH) new CEO, Stephen Hemsley, is shaking up the senior management of the company, appointing Patrick Conway, newly named CEO of the managed care giant’s Optum unit, as the head ...